Analysis Of Income And Expense [Abstract]

Innate Pharma - Filing #858132

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue from sale of goods	—	—	59,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	— EUR
Revenue	—	—	57 674 EUR	—	—	—	—	—	—	—	—	—	—	—	—	24 703 EUR
Material income and expense [abstract]
Research and development expense	—	—	51 663 EUR	—	—	—	—	—	—	—	—	—	—	—	—	47 004 EUR
Finance income (cost)	—	—	546,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	2 347 EUR
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	—	—	22 436 EUR	—	—	—	—	—	—	—	—	—	—	—	—	25 524 EUR
Operating expense	—	—	74 099 EUR	—	—	—	—	—	—	—	—	—	—	—	—	72 528 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	— EUR	428,000 EUR	428,000 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	—	— EUR	— EUR	— EUR	483,000 EUR	— EUR	483,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	— EUR	362,000 EUR	57 741 EUR	— EUR	58 103 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	52 809 EUR	101,000 EUR	— EUR	52 708 EUR